8-Difluoromethoxy-4-Quinolone Derivatives as Anti-Feline Immunodeficiency Virus (FIV) Agents: Important Structural Features for Inhibitory Activity of FIV Replication

Journal of Veterinary Medical Science

Volumn 62, Issue 5, 2000, Pages 499-504

  Kashiwase, Hiroto ^c   Katsube, Tetsushi ^b   Kimura, Tomio ^a   Nishigaki, Takashi ^c   Yamashita, Makoto ^c  

^a DAIICHI SANKYO CO   (Japan)

^b UBE INDUSTRIES LTD   (Japan)

^c Biological Research Laboratories   (Japan)

Author keywords

Antiviral agent; Arylpiperazinyl fluoroquinolone; Feline immunodeficiency virus (FIV); Inhibitor of FIV replication

Indexed keywords

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS;

DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; QUINOLONE DERIVATIVE; TETRAZOLIUM; VIRUS ANTIGEN;

ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; CELL CULTURE; CHEMISTRY; COLORIMETRY; CYTOPATHOGENIC EFFECT; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FELINE IMMUNODEFICIENCY VIRUS; IC 50; PHYSIOLOGY; VIRUS REPLICATION;

ANIMALS; ANTIGENS, VIRAL; CATS; CELLS, CULTURED; COLORIMETRY; CYTOPATHOGENIC EFFECT, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNODEFICIENCY VIRUS, FELINE; INDICATORS AND REAGENTS; INHIBITORY CONCENTRATION 50; QUINOLONES; TETRAZOLIUM SALTS; VIRUS REPLICATION;

EID: 0034183392     PISSN: 09167250     EISSN: None     Source Type: Journal    
DOI: 10.1292/jvms.62.499     Document Type: Article

References (33)

1. Albrecht, R. 1977. Development of antibacterial agents of the nalidixic acid type. Prog. Drug. Res. 21: 9-104.
2. + T cell homeostasis and function in advanced HIV disease. Science 277: 112-116.
3. Baba, M., Okamoto, M., Makino, M., Kimura, Y., Ikeuchi, T., Sakaguchi, T. and Okamoto, T. 1997. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother. 41: 1250-1255.
4. Bendinelli, M., Pistello, M., Lombardi, S., Poli, A., Garzelli, C., Matteucci, D., Ceccherini-Nelli, L., Malvaldi, G. and Tozzini, F. 1995. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin. Microbiol. Rev. 8: 87-112.
5. Brodt, H. R., Kamps, B. S., Gute, P., Knupp, B., Staszewski, S. and Helm, E. B. 1997. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11: 1731-1738.
6. Chu, D. T. W. 1996. The future role of quinolones. Exp. Opin. Ther. Patents 6: 711-737.
7. Cronn, R. C., Remington, K. M., Preston, B. D. and North, T. W. 1992. Inhibition of reverse transcriptase from feline immunodeficiency virus by analogs of 2′-deoxyadenosine-5′-triphosphate. Biochem. Pharmacol. 44: 1375-1381.
8. Egberink, H., Borst, M., Niphuis, H., Balzarini, J., Neu, H., Schellekens, H., De Clercq, E., Horzinek, M. and Koolen, M. 1990. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc. Natl. Acad. Sci. U.S.A. 87: 3087-3091.
9. Egberink, H. F., Hartman, K. and Horzinek, M. C. 1991. Chemotherapy of feline immunodeficiency virus infection. J. Am. Vet. Med. Assoc. 199: 1485-1487.
10. Egger, M., Hirschel, B., Francioli, P., Sudre, P., Wirz, M., Flepp, M., Rickenbach, M., Malinverni, R., Vernazza, P., Battegay, M. and the Swiss HIV Cohort Study. 1997. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Br. Med. J. 315: 1194-1199.
11. Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D. D., Richman, D. D. and Siliciano, R. F. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
12. Hagihara, M., Kashiwase, H., Katsube, T., Kimura, T., Komai, T., Momota, K., Ohmine, T., Nishigaki, T., Kimura, S. and Shimada, K. 1999. Synthesis and anti-HIV activity of aryl piperazinyl fluoroquinolones: a new class of anti-HIV agents. Bioorg. Med. Chem. Lett. 9: 3063-3068.
13. Hartmann, K., Donath, A., Beer, B., Egberink, H. F., Horzinek, M. C., Lutz, H., Hoffman-Fezer, G., Thum, I. and Thefeld, S. 1992. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet. Immunol. Immunopathol. 35: 167-175.
14. Hayes, K. A., Lafrado, L. J., Erickson, J. G., Marr, J. M. and Mathes, L. E. 1993. Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats. J. Acquir. Immune. Defic. Syndr. 6: 127-134.
15. Hayes, K. A., Wilkinson, J. G., Frick, R., Francke, S. and Mathes, L. E. 1995. Early suppression of viremia by ZDV does not alter the spread of feline immunodeficiency virus infection in cats. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 9: 114-122.
16. Hogg, R. S., O'Shaughnessy, M. V., Gataric, N., Yip, B., Craib, K., Schechter, M. T. and Montaner, J. S. G. 1997. Decline in deaths from AIDS due to new antiretrovirals. Lancet 349: 1294.
17. Hooper, D. C. and J. S. Wolfson. 1993. Mechanisms of quinolone action and bacterial killing. pp. 53-75. In: Quinolone Antimicrobial Agents, 2nd ed. (Hooper, D. C. and Wolfson, J. S. eds.), American Society for Microbiology, Washington, D.C.
18. Kashiwase, H., Ishimura, M., Ishikawa, Y. and Nishigaki, T. 1997. Characterization of one monoclonal antibody against feline immunodeficiency virus p24 and its application to antigen capture ELISA. J. Virol. Methods 68: 183-192.
19. Kashiwase, H., Momota, K., Ohmine, T., Komai, T., Kimura, T., Katsube, T., Nishigaki, T., Kimura, S., Shimada, K. and Furukawa, H. 1999. A new fluoroquinolone derivative exhibits inhibitory activity against human immunodeficiency virus type 1 replication. Chemotherapy 45: 48-55.
20. Kimura, T. and Katsube, T. December 1993. European Patent EP0572259A1.
21. Meers, J., Del Fierro, G. M., Cope, R. B., Park, H. S., Greene, W. K. and Robinson, W. F. 1993. Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine. Arch. Virol. 132: 67-81.
22. Mitscher, L. A., Devasthale, P. and Zavod, R. 1993. Structure-activity relationships. pp. 3-51. In: Quinolone Antimicrobial Agents, 2nd ed. (Hooper, D. C. and Wolfson, J. S. eds.), American Society for Microbiology, Washington, D.C.
23. Miyazawa, T. and Mikami, T. 1993. Biological nature of feline immunodeficiency virus. J. Vet. Med. Sci. 55: 519-526.
24. Mouton, Y., Alfandari, S., Valette, M., Cartier, F., Dellamonica, P., Humbert, G., Lang, J. M., Massip, P., Machali, D., Leclercq, P., Modai, J. and Portier, H. 1997. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 11: F101-F105.
25. Nozaki-Renard, J., Iino, T., Sato, Y., Marumoto, Y., Ohta, G. and Furusawa, M. 1990. Fluoroquinolones protect the human lymphocyte CEM cell line from HIV-1-mediated cytotoxicity. Cell Struct. Funct. 15: 295-299.
26. Nozaki-Renard, J., Iino, T., Sato, Y., Marumoto, Y., Ohta, G. and Furusawa, M. 1990. A fluoroquinolone (DR-3355) protects human lymphocyte cell lines from HIV-1-induced cytotoxicity. AIDS 4: 1283-1286.
27. Palella, F. J. Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., Holmberg, S. D. and the HIV Outpatient Study Investigators. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl. J. Med. 338: 853-860.
28. Pedersen, N. C., Ho, E. W., Brown, M. L. and Yamamoto, J. K. 1987. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235: 790-793.
29. Remington, K. M., Chesebro, B., Wehrly, K., Pedersen, N. C. and North, T. W. 1991. Mutants of feline immunodeficiency virus resistant to 3′-azido-3′-deoxythymidine. J. Virol. 65: 308-312.
30. Shen, L. L. 1993. Quinolone-DNA interaction. pp. 77-95. In: Quinolone Antimicrobial Agents, 2nd ed. (Hooper, D. C. and Wolfson, J. S. eds.), American Society for Microbiology, Washington, D.C.
31. Tanabe-Tochikura, A., Tochikura, T. S., Blakeslee, J. J. Jr., Olsen, R. G. and Mathes, L. E. 1992. Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro. Antiviral Res. 19: 161-172.
32. Wlodawer, A., Gustchina, A., Reshetnikova, L., Lubkowski, J., Zdanov, A., Hui, K. Y., Angleton, E. L., Farmerie, W. G., Goodenow, M. M., Bhatt, D., Zhang, L. and Dunn, B. M. 1995. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat. Struct. Biol. 2: 480-488.
33. Wong J. K., Hezareh, M., Gunthard, H. F., Havlir, D. V., Ignacio, C. C., Spina, C. A. and Richman, D. D. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.